ProCE Banner Activity

My Approach to Biomarker Testing in Advanced NSCLC

Clinical Thought
To benefit from targeted therapies for patients with advanced NSCLC, it is imperative that clinicians use biomarker testing to identify potential actionable gene aberrations. In this commentary, Joel Neal, MD, PhD, discusses his approach to this dynamic aspect of clinical care.

Released: May 11, 2020

Expiration: May 10, 2021

Share

Faculty

Joel W. Neal

Joel W. Neal, MD, PhD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Celgene

Loxo Oncology subsidiary of Eli Lilly

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Joel W. Neal, MD, PhD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Joel Neal, MD, PhD, has disclosed that he has received funds for research support from Adaptimmune, Boehringer Ingelheim, Exelixis, Genentech/Roche, GlaxoSmithKline, Merck, Nektar, Novartis, and Takeda, and consulting fees from AstraZeneca, Calithera, Exelixis, Genentech/Roche, Jounce, Lilly, and Takeda.